Overview

Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

Status:
NOT_YET_RECRUITING

Trial end date:
2033-07-01

Target enrollment:

Participant gender:

Summary

This phase II trial is to answer the question of "can adding the study drug, asciminib to usual treatment improve how chemotherapy works against Ph+ Acute Lymphoblastic Leukemia (ALL) and is this approach better than the usual approach for Ph+ALL?"

Phase:

PHASE2

Details

Lead Sponsor:

SWOG Cancer Research Network

Collaborator:

Novartis Pharmaceuticals

Treatments:

Maintenance